<DOC>
	<DOCNO>NCT00400738</DOCNO>
	<brief_summary>Treatment protease inhibitor might benefit HIV patient . Laboratory data show combination saquinavir lopinavir ritonavir may good regimen . This study explore idea .</brief_summary>
	<brief_title>The Pharmacokinetics Double Boosted Protease Inhibitors Antiretroviral-naive HIV-1 Infected Patients</brief_title>
	<detailed_description>Treatment protease inhibitor might benefit HIV patient , experience problem antiretrovirals drug class . Another reason use protease inhibitor remain class spar . This leave option use class future , instance case drug resistance . Laboratory data show combination saquinavir lopinavir ritonavir may good regimen . This study explore idea .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>1. write informed consent 2 . ARVna√Øve 3 . HIV1 infect Thai male female &gt; 18 year old 4 . Documented positive test HIV1 infection 1 . Inability understand nature extent study procedure require . 2 . Pregnancy lactate 3 . Active opportunistic infection 4 . ALT/ AST 2x upper limit 5. creatinine 1.5 time upper limit 6 . Smoke cigarettes 10 cigarette day . 7 . Drink alcohol 2 unit day 8 . Relevant history current condition , illness might interfere drug absorption , distribution , metabolism excretion . 9 . Use concomitant medication may interfere pharmacokinetics lopinavir/ritonavir saquinavir</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>HIV-1 infection</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>protease inhibitor</keyword>
	<keyword>double boosted protease inhibitor</keyword>
	<keyword>PIs</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>